Bromoacetamido-PEG5-DOTA manufacturers
|
| | Bromoacetamido-PEG5-DOTA Basic information |
| Product Name: | Bromoacetamido-PEG5-DOTA | | Synonyms: | Bromoacetamido-PEG5-DOTA;1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-(23-bromo-2,22-dioxo-6,9,12,15,18-pentaoxa-3,21-diazatricos-1-yl)- | | CAS: | 2353410-19-0 | | MF: | C30H55BrN6O13 | | MW: | 787.69 | | EINECS: | | | Product Categories: | | | Mol File: | 2353410-19-0.mol |  |
| | Bromoacetamido-PEG5-DOTA Chemical Properties |
| Boiling point | 976.6±65.0 °C(Predicted) | | density | 1.314±0.06 g/cm3(Predicted) | | pka | 1.83±0.10(Predicted) | | form | Oil | | color | White to off-white |
| | Bromoacetamido-PEG5-DOTA Usage And Synthesis |
| Description | Bromoacetamido-PEG3-DOTA is a PEG linker containing a bromine moiety and a t-butyl protecting group. The hydrophilic PEG spacer increases the water solubility of a compound in aqueous media. The bromide (Br) is a very good leaving group for nucleophilic substitution reactions. The DOTA group can be ionized and is susceptible for chelating di- and trivalent cations. | | Uses | Bromoacetamido-PEG5-DOTA is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs[1]. | | IC 50 | PEGs | | References | [1] An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562 DOI:10.1016/j.ebiom.2018.09.005 |
| | Bromoacetamido-PEG5-DOTA Preparation Products And Raw materials |
|